Episode Details
Back to Episodes
Clearway Health, John Nosta, Perigon 360, and Psychedelics in Practice | TWIRx
Description
TWIRx News:
The FDA plans to remove 12 peptide bulk drug substances from Category 2 of the Section 503A compounding list after their nominations were withdrawn. For compounders, the key issue is that this change does not automatically make compounding these substances permissible, leaving pharmacies exposed to ongoing regulatory uncertainty until the FDA makes further decisions.
A nationwide Class II recall has been issued for Xanax XR 3 mg tablets in 60-count bottles, lot 8177156, after the product failed dissolution testing. Pharmacists should immediately locate and quarantine affected stock while reminding patients not to stop benzodiazepine therapy suddenly without direction from a healthcare provider.
Community pharmacies are taking on a larger role in wound care by serving as an accessible first point of contact for patients with minor injuries. Pharmacists can help assess wounds, recommend appropriate over-the-counter treatment, watch for warning signs of complications, and refer patients for higher-level care when needed.
Special sponsor interview with Allison Arant with Clearway Health.
Featured interview with the World's Leading Innovation Theorist John Nosta
Guests & sponsors of today's TWIRx, Perigon 360 Pharmacy with Chris Antypas PharmD and ed Mills
And a bonus interview with Dr. Andy Krut PharmD, on Psychedelics (e.g., LSD, psilocybin, DMT)